A study published in the British Journal of Urology International showed PSA testing predicted prostate cancer more effectively in men with high-risk BRCA mutations than in the general population.
There is currently no national screening programme for prostate cancer due to a lack of evidence for the benefit of PSA testing.
Mutations in genes BRCA1 and BRCA2 increase the risk of prostate cancer by up to seven- and two-fold respectively.
Researchers analysed data from 300 men aged 40-69 involved in the IMPACT trial.
A total of 205 men with BRCA1 or BRCA2 mutations and 95 non-carriers were offered annual PSA testing. Of these, 24 who had elevated PSA levels were given a follow-up biopsy.
The tests revealed that a higher proportion of mutation carriers had prostate cancer than non-carriers, with diagnosis rates of 3.9% cent and 2.1% respectively.
This translates to a predictive value of 48% for those with the mutations, compared with 24% among non-carriers.
The UK National Screening Committee will issue its next review of the evidence in March 2011.